Synthesis and molecular evaluation of 15-deoxy-[delta]¹²,¹⁴-prostamide J₂ as a novel anti-skin cancer agent / by Daniel A. Ladin.
| Author/creator | Ladin, Daniel A. author. |
| Other author | Van Dross-Anderson, Rukiyah, degree supervisor. |
| Other author | East Carolina University. Department of Pharmacology and Toxicology. |
| Format | Theses and dissertations |
| Publication | [Greenville, N.C.] : [East Carolina University], 2017. |
| Description | 147 pages : illustrations (some color). |
| Supplemental Content | Access via ScholarShip |
| Subjects |
| Series | ECU Brody School of Medicine dissertation ECU Brody School of Medicine dissertation. UNAUTHORIZED |
| Summary | Skin cancers including non-melanoma skin cancer (NMSC) and melanoma are the most common form of cancer in the United States and thus represent a substantial burden to the health care system. Current chemotherapeutic treatments for skin cancer cause harmful side effects due to lack of tumor-cell selectivity. Our group previously found that the endocannabinoid, arachidonoyl-ethanolamide (AEA), induces apoptosis in tumor but not non-tumor cell lines through its metabolism to novel J-series prostaglandin-ethanolamides (prostamides). Therefore, the goal of this study was to synthesize the novel prostamide, 15-deoxy-[delta]¹²,¹⁴-prostamide J₂ (15d-PMJ₂) and determine the molecular mechanism of its antineoplastic activity. To our knowledge, we are the first group to successfully synthesize and biologically characterize a J-series prostamide. 15d-PMJ₂ exhibited potent and selective apoptotic properties in both non-melanoma and melanoma skin cancers. Furthermore, 15d-PMJ₂ was a potent inducer of tumor cell apoptosis in vivo. Induction of endoplasmic reticulum (ER) stress was required for 15d-PMJ₂ -mediated cancer cell death and was an important determinant of selective toxicity. This project also conducted a targeted structure-activity assessment of the electrophilic double bond, definitively showing this moiety as the molecular "warhead" necessary for the cytotoxic activity. Taken together, these data provide sound evidence that 15d-PMJ₂ may provide a clinical alternative for treatment of non-melanoma and melanoma skin cancer with less adverse effects. |
| General note | Presented to the faculty of the Department of Pharmacology and Toxicology |
| General note | Advisor: Rukiyah Van Dross-Anderson |
| General note | Title from PDF t.p. (viewed March 20, 2018). |
| Dissertation note | Ph.D. East Carolina University 2017. |
| Bibliography note | Includes bibliographical references. |
| Technical details | System requirements: Adobe Reader. |
| Technical details | Mode of access: World Wide Web. |
Availability
| Library | Location | Call Number | Status | Item Actions |
|---|---|---|---|---|
| Electronic Resources | Access Content Online | ✔ Available |